Abstract
We studied the effect of pirenzepine, a cholinergic antagonist, on the GH response to GH-releasing hormone (GHRH) in 6 obese children (4 males and 2 females) aged 5.3-12.8 years with excess body weight ranging from 42 to 125% for their stature. A GHRH test was also performed in 8 short normal children (5 males and 3 females, age 6.8-11 years) studied as controls. In the obese patients two GHRH (GHRH 1-29, 1 μg/Kg iv) tests were performed 3-7 days apart in random order. Sixty min before the GHRH bolus the patients received placebo or pirenzepine (50 mg po). Mean peak and area under the curve (AUC) responses to GHRH were significantly lower in the obese subjects than in the control group. Administration of pirenzepine caused a significant reduction of both peak and AUC responses to GHRH in all obese children. Our findings show that administration of a cholinergic antagonist suppresses the already blunted GH response to GHRH in obese children. These and other previous findings indicate the presence of an intact somatostatinergic system in obesity.
| Original language | English |
|---|---|
| Pages (from-to) | 163-167 |
| Number of pages | 5 |
| Journal | Acta Medica Auxologica |
| Volume | 25 |
| Issue number | 3 |
| Publication status | Published - 1993 |
Fingerprint
Keywords
- GH
- GHRH
- obesity
- pirenzepine
- somatostatin
ASJC Scopus subject areas
- Medicine(all)
Cite this
The effect of pirenzepine on the growth hormone response to growth hormone-releasing hormone in obese children. / Loche, S.; Cappa, M.; Faedda, A.; Pintor, C.
In: Acta Medica Auxologica, Vol. 25, No. 3, 1993, p. 163-167.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The effect of pirenzepine on the growth hormone response to growth hormone-releasing hormone in obese children
AU - Loche, S.
AU - Cappa, M.
AU - Faedda, A.
AU - Pintor, C.
PY - 1993
Y1 - 1993
N2 - We studied the effect of pirenzepine, a cholinergic antagonist, on the GH response to GH-releasing hormone (GHRH) in 6 obese children (4 males and 2 females) aged 5.3-12.8 years with excess body weight ranging from 42 to 125% for their stature. A GHRH test was also performed in 8 short normal children (5 males and 3 females, age 6.8-11 years) studied as controls. In the obese patients two GHRH (GHRH 1-29, 1 μg/Kg iv) tests were performed 3-7 days apart in random order. Sixty min before the GHRH bolus the patients received placebo or pirenzepine (50 mg po). Mean peak and area under the curve (AUC) responses to GHRH were significantly lower in the obese subjects than in the control group. Administration of pirenzepine caused a significant reduction of both peak and AUC responses to GHRH in all obese children. Our findings show that administration of a cholinergic antagonist suppresses the already blunted GH response to GHRH in obese children. These and other previous findings indicate the presence of an intact somatostatinergic system in obesity.
AB - We studied the effect of pirenzepine, a cholinergic antagonist, on the GH response to GH-releasing hormone (GHRH) in 6 obese children (4 males and 2 females) aged 5.3-12.8 years with excess body weight ranging from 42 to 125% for their stature. A GHRH test was also performed in 8 short normal children (5 males and 3 females, age 6.8-11 years) studied as controls. In the obese patients two GHRH (GHRH 1-29, 1 μg/Kg iv) tests were performed 3-7 days apart in random order. Sixty min before the GHRH bolus the patients received placebo or pirenzepine (50 mg po). Mean peak and area under the curve (AUC) responses to GHRH were significantly lower in the obese subjects than in the control group. Administration of pirenzepine caused a significant reduction of both peak and AUC responses to GHRH in all obese children. Our findings show that administration of a cholinergic antagonist suppresses the already blunted GH response to GHRH in obese children. These and other previous findings indicate the presence of an intact somatostatinergic system in obesity.
KW - GH
KW - GHRH
KW - obesity
KW - pirenzepine
KW - somatostatin
UR - http://www.scopus.com/inward/record.url?scp=0027713273&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027713273&partnerID=8YFLogxK
M3 - Article
VL - 25
SP - 163
EP - 167
JO - Acta Medica Auxologica
JF - Acta Medica Auxologica
SN - 0001-6004
IS - 3
ER -